INTRODUCTION
Mung bean is widely eaten as a porridge and/or vermicelli in China, Southeast Asia, and India. It is also a Chinese medical agent, with antifebrile effects [1, 2] .
The pol yphenol component of the mung bean seed coat has been shown improvement of plasma glucose levels and antioxidant property [3, 4] , while the starch of mung bean increases suppression of plasma glucose levels [5] . However, there are a few reports on the physiological effects of mung bean protein.
The main component of mung bean protein is 8Sα globulin, with a structure very similar to that of soybean β-congl ycinin [6] , which has been reported to have positive effects on lipid and glucose metabolism [7, 8] . Therefore, mung bean protein is expected to have similar effects owing to its structural similarit y to β-congl ycinin. We have reported the plasma trigl yceride-lowering effect of mung bean protein due to improve d insulin sensitivit y in rats [9] .
Type 2 diabetes is a lifest yle-related disease that has spread worldwide, especiall y in developed countries. With the progression of t ype 2 diabetes s ymptoms, microscopic plasma vessels in the body are graduall y destroyed, causing serious damage to various organs of the body [10] . The complications of type 2 diabetes progression include severe conditions such as diabetic neuropathy, diabetic retinopathy, and diabetic nephropathy [11] [12] [13] .
This study examined the effects of mung bean protein of improving glucose metabolism by assessing insulin sensitivity in prediabetes subjects.
MATERIALS AND METHODS

Experimental food
Isolated mung bean protein (GLUCODIA TM ) was manufactured using a method identical to that used for the production of isolated soy protein and administered in the form of candy. GLUCODIA TM , consisting of 92% mung bean protein, 3% minerals, and 5% water, was sterilized for food use and spray dried. The composition of a test candy is shown in Table 1 . The test candy contained 0.625 g of mung bean protein per piece. In the control experiment, placebo candy with the same taste as the test candy was produced by replacing mung bean protein with the milk protein casein (Table 1) . 
Subjects
All of the test subjects were Japanese men and women 20 to 59 years of age.
Individuals undergoing treatment for hyperlipidemia, diabetes , or liver dysfunction or with food allergies were excluded from the study. According to the guidelines of the Japan Diabetes Societ y, prediabetes is defined as a fasting plasma glucose level of 110 -125 mg/dl or 2-hour plasma glucose level (2-h PG) using the 75 g glucose tolerance test (OGTT) of 140-200 mg/dl [14] . This study screened patients for prediabetes patients based on health diagnostic results .
Furthermore, some subjects were also screened for hypertriglyceridemia (fasting plasma trigl yceride (TG); 150-400 mg/dl). The subjects were screened at two medical examination s (Pre-trial 1 and 2) before trial enrolment.
A total of 189 potential subjects visited the facilit y for testing at Pre -trial 1.
A specific history was obtained from these potential subjects, and they underwent a physical examination an d laboratory tests. Based on the results of testing at individuals were selected as trial subjects. These subjects visited the medical facilit y for testing on the date that diet consumption started. A specific history was obtained from these subjects ; then they underwent a physical examination and laboratory tests.
Test design
This study was a double-blind placebo-controlled design that lasted for 12 weeks.
The subjects were assigned at random to one of two groups: the test group consumed onl y the test candy containing GLUCODIA TM (n = 23), while the placebo group consumed onl y the casein-containing placebo candy (n = 22).
During the consumption period, subjects visited the medical facilit y twice during their consumption of that diet (6 weeks and 12 weeks from the start of the test), and plasma samples were collected. The subjects in the test group were instructed to consume two pieces of candy twice dail y, for a total of 2. 
Ethical considerations
The protocol for this trial closel y followed the ethical principles set out in the Declaration of Helsinki (2008 revision The potential subjects were selected based on inclusion and exclusion criteria in the trial protocol. In order to protect the human rights of the subjects, aspects such as the subject's health, age, s ex, abilit y to provide consent, his or her dependence on the principal investigators, and whether subjects were participating in other trials were considered. Whether or not subjects would be asked to participate in this trial was carefull y considered. Car eful attention was given to personal information on the subjects involved in this trial with regard to consent forms, case reports, han dling of raw data, and publication of data. When case reports were drafted, manuscripts were published, or data were pres ented, measures were taken to prevent individual trial subjects from being identified (such as designating subjects with a subject identification number), and subjects' personal information was protected.
RESULTS
Subjects
During the evaluation of efficacy, data from three subjects would markedly reduce the accuracy of that evaluation . Therefore, these three subjects were excluded from anal ysis. The rationales for exclusion were: (1) Fasting plasma glucose (FPG) and insulin levels marke dly higher than the mean ± 2SD prior to consumption of the test diet. (2) Subjects with insulin levels equal to reference levels due to hemol ysis of laboratory specimens.
Therefore, data from 42 subjects were anal yzed (Fig. 1) .
The background information of the 42 subjects in both groups is summarized in Table 2 . The FPG values in the test and placebo groups were 97 ± 2 and 95 ± 2 mg/dl; the TG values were 130 ± 13 and 114 ± 12 mg/dl respectivel y. There were no significant diff erences in the initial FPG and TG between the test and placebo groups. The body mass indexes (BMIs) in the test and placebo groups were 29.2 ± 1.0 and 26.2 ± 1.3 kg/m 2 respectivel y. There was a significant tendency in the difference between the two groups (p < 0.1).
Evaluation of safety
The results of the physical examination reflected physiological variations in the subjects, so the principal investigators deemed that the test food posed no problems in terms of safet y. Additionall y, some laboratory results fell outside the standard value ranges depending on the individual subject, but these results were specific to the subject or they reflected physiological variations. The principal investigators deemed that the test food posed no clinical problems.
The subjects reported several subjective symptoms during the trial, but these s ymptoms were due to lifest yle, seasonal factors, or physical condition or were pre-existing symptoms. Since the severity of these symptoms was minimal, the *, ** show significant differenes between initial and final data (* p<0.05, ** p<0.01), and # show a significant tendency between initial and final data (p<0.1).
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FPG
The mean FPG results are shown in Table 2 and Fig. 2a . The FPG level in the test group did not change during the consumption period. In contrast, the FPG level in the placebo group significantl y increased from 95 ± 2 to 100 ± 3 mg/dl.
Additionall y, the net changes in FPG level in the test and placebo group s were −0.4 ± 2.0 and 5.4 ± 2.5 mg/dl respectivel y, but the difference between the two groups was not significant (p = 0.114, Fig. 2a ).
Insulin
The results of insulin testing are shown in Table 2 and Fig. 2b . The fasting insulin level in the test group showed almost no change (8.5 ± 1.0 to 8.9 ± 1.1 μU/ml). In the placebo group , the fasting insulin level significantl y increased from 6.6 ± 1.0 to 9.6 ± 1.6 μU/ml (p < 0.05, Table 2 ) . However, the net change did not differ significantly between the test and placebo groups (p = 0.111, Fig   2b) .
Homeostatic Model Assessment for Insulin Resistance
Homeostatic model assessment for insulin resistance values (HOMA-IR) were calculated as follows based on each subject's plasma glucose and insulin levels.
HOMA-IR = fasting insulin levels (μU/m l) × FPG levels (mg/ dl) /405.
Similar to the insulin level, HOMA-IR values in the test group showed almost no change. In the placebo group, HOMA -IR values significantl y increased from 1.59 ± 0.23 to 2.52 ± 0.51 (p < 0.01, Table 2 ). However, the net change in HOMA-IR values showed no significant difference between the two groups (p = 0.118, Fig. 2c ).
Glycated hemoglobin (HbA1c)
There were no significant differences in HbA1c levels between or within groups (Table 2) .
TG and cholesterol
The TG level in the test group changed little (130 ± 13 to 131 ± 14 mg/dl). In the placebo group, the TG level increased from 114 ± 12 to 123 ± 20 mg/dl.
Significant differences in TG levels were not noted between or within groups (Table 2) .
Because there was a difference in the initial values between the two groups, TG levels were analyzed , focusing on subjects with high trigl yceride levels (>150 mg/dl). The TG level in the test group was reduced. In contrast, the TG level increased in the placebo group (Table 3) .
The total cholesterol level in the placebo group increased significantl y (p < 0.05), and LDL cholesterol level increased with a significant tendency (p < 0.1).
In the test group, total cholesterol and LDL cholesterol level showed almost no change ( Table 2) .
OGTT
Plasma glucose levels 120 min after administration of the glucose load were lower in the test group than those in the placebo group at the start and end of the diet consumption (Table 4a and b). In contrast, insulin levels showed the opposite trend. There were no significant difference s between groups for either glucose or insulin levels . Background information on obese subjects In this study, the BMI in the placebo group was lower than that of the test group (p<0.1, Table 2 ). Among the total subjects, those with a BMI above 25 kg/m 2 were selected and anal yzed as obese subjects. The background information on these subjects is shown in Table 5 . The initial BMIs in the test and placebo groups were 30.2 ± 0.9 and 30.0 ± 1.1 kg/m 2 respectively. No significant differences were observed between the groups .
FPG levels in obese subjects
There was little change in FPG level in the test group (96 ± 2 mg/dl prior to diet consumption vs. 95 ± 3 mg/dl after 12 weeks of diet consumption ). In contrast, the FPG level in the placebo group increased from 96 ± 2 to 103 ± 4 mg/dl, a difference with a significant tendency ( p < 0.1, Table 5 ). The net changes in FP G level in the test and placebo group s were −1.3 ± 2.2 and 7.0 ± 3.5 mg/dl respectivel y, which was a significant difference (p < 0.05, Fig. 3a ). Table 5 ) Initial and final data of clinical characteristics and plasma levels of obese study subjects.
* shows a significant differenes between initial and final data (p<0.05), and # show a significant tendency between initial and final data (p<0.1).
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Insulin levels of obese subjects The fasting insulin level in the test group showed almost no change ( 9.4 ± 1.0 to 9.7 ± 1.2 μU/ml). The level in the placebo group significantl y increased from 9.2 ± 0.8 to 13.6 ± 2.0 μU/ml (p < 0.05), and a significant difference between the two groups was observed (p < 0.05, Table 5 ). Additionall y, the net changes in insulin levels in the test and placebo group s were 0.4 ± 0.8 and 4.4 ± 2.2 μU/ml respectivel y, and there was significant tendency between the two groups (p < 0.1, Fig. 3b ).
HOMA-IR values in obese subjects
HOMA-IR in the test group showed almost no change , similar to the findings of the total subjects (Table 5 ). In the placebo group, HOMA -IR increased significantl y, from 2.2 ± 0.2 to 3.6 ± 0.7 (p < 0.05). The net change of HOMA -IR showed a significant tendency between the test and placebo groups (p < 0.1, Fig   3c) .
TG and cholesterol levels in obese subjects
Trigl yceride levels slightl y decreased in the test group, while those in the placebo group increased , but the difference was not significant. Total cholesterol levels rose in the control group with a significant tendency (p < 0.1), but the LDL cholesterol levels did not change (Table 5) .
DISCUSSION
This study included prediabetes subjects, based on the diabetes diagnostic guidelines of the Japan Diabetes Society [14] . The subjects in this study were considered to be positive for prediabetes based on 2-h PG values after an OGTT, which is one of the diagnostic methods. The FPG level s in the subjects were within the normal range.
In this study, the 2-h PG value after OGTT in the test group decreased to 153 ± 8 mg/dl from 159 ± 8 mg/dl. The values in the placebo group did not change (Table 4a and b). The insulin value in the OGTT was high in the test group, which suggests that insulin was sufficientl y secreted to quickl y lower plasma glucose levels to the steady-state value. FPG levels increased significantl y after 12 weeks of diet consumption in the placebo group but changed little in the test group (Table 2 and Fig 2a) . Additionall y, fasting insulin levels in the placebo group increased significantly after 12 weeks of diet consumption . However, in the test group, no changes in the fasting insulin levels were observed (Table 2 and Fig   2b) .
In this study, the initial mean BMI differed significantl y between the two groups ( Table 2) . Therefore, data from obese subjects (BMI > 25 kg/m 2 ) were anal yzed. In these subjects, the effects of improved FPG and insulin levels were greater than those for the total subjects (Table 5 and Fig 3a -c) . A principal component of mung bean protein is 8Sα globulin, which is structurall y similar to that of soybean β -congl ycinin [5] . Soybean β -congl ycinin reportedl y improves insulin sensitivit y in rats and decreases fasting insulin levels or reduces visceral fat and body fat in clinical studies [7] . In previous study [7] , the reducing effect of visceral fat by β-congl ycinin was remarkabl y observed in obese subjects with visceral fat areas greater than 100 cm 2 . Thus, the same trend as the effect of β-congl ycinin was observed in mung bean protein.
This clinical study was conducted from the summer to the autumn. Seasonal variations are frequentl y observed in the metabolism of mammals [15] . Some human physiological parameters (such as blood pressure, heart rate, lipid profile, insulin, and serum cortisol) are influenced by seasonal cycles [16] [17] [18] [19] [20] They reported increased and decreased body fat and HbA1c levels in winter and summer respectivel y, without any appreciable change in body weight.
In the current study, FPG and insulin levels increased in the placebo group, but there was little change in HbA1c levels in either group. HbA1c, which is the product of non -enz ymatic gl ycation of the hemoglobin molecule, reflects plasma glucose levels throughout the previous 2 -3 months [30] . Significant increases in FPG and insulin lev els in the placebo group were considered the result of these naturall y occurring factors preceding the increase of HbA1c level s. Therefore, if this study were continued through the winter months, it is presumed that HbA1c levels would have increased. Mung bean protein may control these spontaneous variations and act to stabilize FPG and insulin levels.
Insulin resistance indicates a state where insulin action fails to keep up with insulin levels in the plasma owing to decreased signal transducers for the insulin receptor. Accumulation of visceral fat is a key factor for the induction of insulin resistance [31] .
In the current study, mung bean protein was shown to control spontaneous seasonal variation s and to stabilize FPG and insulin levels. These effects were greater in obese subjects (Table 5 and Fig 3a -c) . These findings indicate that mung bean protein may improve insulin sensitivit y through the accumulation of visceral fat. TG levels largel y decreased as a result of analysis limited to the subject of hyperlipidemia (Table 3) . Soybean β -congl ycinin reported ly improves high TG levels by induction of β -oxidation, downregulation of fatt y acid s ynthase, and inhibition of TG absorption in m ice and rats [32, 33] . Consumption of mung bean protein may act in a similar manner. Indeed, mung bean protein has been reported to reduce plasma TG levels by the active suppression of fatt y acid s ynthase by inhibition of sterol regulatory element -binding protein 1 (SREBP-1) expression in the rat liver [9] . In this study, trigl yceride, total -cholesterol and LDL-cholesterol levels increased in the placebo group (Table 2 , 3 and 5). Some literature reported that casein increased the cholesterol level as casein -induced hypercholesterolemia in swine [34] . But in our previous clinical study [7] , these levels in the placebo, casein group almost no change. Thus, this phenomenon was suggested to be induced as one of the seasonal variations observed in the metabolism of mammals [15] .
Mung bean is a traditional food in Asia. It is generall y eaten as a boiled porridge, and mung bean starch is used in noodle form , but the protein itself is not t ypicall y consumed as a food. Mung bean protein is safe r than soy protein in terms of being a non-geneticall y modified organism and not typicall y an allergic source. Future studies should confirm the effects of mung bean protein in subjects with higher levels of insulin resistance.
CONCLUSIONS
Mung bean protein acted to maintain fasting blood glucose and insulin levels constant by controlling these seasonal variations . These effects were particularl y observed in obese subjects. It is useful for the maintenance of the insulin sensitivit y to keep insulin secretion constant. Mung bean protein may improve
